期刊文献+

外周血Th17细胞及Treg细胞检测对系统性红斑狼疮病情的评估价值 被引量:9

Value of determining Th17 and regulatory T cells in the peripheral blood in evaluating patients with systemic lupus erythematosus
暂未订购
导出
摘要 目的探讨外周血Th17细胞及Treg细胞检测对系统性红斑狼疮(systemic lupus erythematosus,SLE)病情评估的价值。方法以2014年1月至2016年6月在山西医科大学第二医院风湿科就诊的100例SLE患者(非活动组患者37例,活动组患者63例)及30名健康者为研究对象。采用分选流式细胞仪检测外周血Th17细胞、Treg细胞百分数,采用流式细胞仪微球捕获芯片技术检测血清白介素-17(interleukin-17,IL-17)浓度,ELISA方法检测血清转化生长因子β(transforming growth factorβ,TGF-β)浓度。结果 (1)SLE患者组Th17细胞百分数显著高于正常对照组(P<0.05),且活动组Th17细胞显著高于非活动组(P<0.05)。(2)SLE患者组Treg细胞显著低于正常对照组(P<0.05),SLE活动组Treg细胞显著低于非活动组(P<0.05)。(3)SLE活动组Th17/Treg显著高于SLE非活动组与正常对照组(P<0.05)。(4)SLE患者组IL-17显著高于正常对照组(P<0.05),活动组IL-17显著高于非活动组(P<0.05);患者组与正常对照组、SLE活动组与非活动组TGF-β差异均无统计学意义(P>0.05)。结论 Th17细胞及Treg细胞参与SLE的发生、发展,Th17/Treg可以作为SLE疾病活动和病情评价的可靠指标。 Objective To study the value of determining Th17 and regulatory T cell(Treg)in the peripheral blood in evaluating patients with systemic lupus erythematosus(SLE). Methods This study included 100 patients with SLE (37 patients were in inactive SLE group and 63 patients were in active group) and 30 normal controls. Percentage of Th17 and Treg in the peripheral blood were detected by flow cytometry. The concentration ofinterleukin-17 was detected by cytometric bead array(CBA). The concentration of transforming growth factor-β was detected by ELISA. Results (1)The percentage of Th17 in the peripheral blood in patients with SLE was higher than that in normal controls (P〈0.05), and the percentage of Th17 in active SLE patients was higher than that in inactive SLE patients (P〈0.05). (2)The percentage of Treg in patients with SLE was lower than that in normal controls(P〈0.05), and the percentage of Treg in active SLE was lower than that in inactive SLE patients(P〈0.05). (3)Tote percentage of Th17/Treg level in active SLE patients was higher than that in inactive SLE patients and normal controls(P〈0.05). (4)The concentration ofinterleukin-17 in patients with SLE was higher than that in normal controls (P〈0.05), and the concentration of interleukin-17 in active SLE patients was higher than that in inactive SLE patients and normal controls(P〈0.05). The concentration of TGF-β had no difference between SLE patients and normal controls(P〉0.05), and it had no difference between active SLE patients and inactive SLE patients(P〉0.05). Conclution Th17 and Treg contribute to the pathogenesis of SLE, and Thl7/Treg level can be the reliable index of SLE condition evaluation.
作者 郝慧琴 张少然 李小峰 陈俊伟 罗静 吕志勤 HAO Hui-qin, ZHANG Shao-ran, LI Xiao-feng, CHEN Jun-wei, LUO Jing, LYU Zhi-qin.(Department of Rheumatology, Shanxi University of Traditonal Chinese Medicine, Taiyuan 030012, Chin)
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2018年第3期242-244,共3页 Chinese Journal of Practical Internal Medicine
基金 山西省科技攻关项目(20140313012-3)
关键词 红斑狼疮 系统性 T淋巴细胞 辅助诱导 流式细胞术 lupus erythematosus, systemic T-lymphocytes, helper-inducer flow cytometry
  • 相关文献

参考文献3

二级参考文献34

  • 1杨宁,赵成,刘布骏,孙凌云.结缔组织病并发肺动脉高压110例临床分析[J].中华风湿病学杂志,2007,11(9):552-555. 被引量:20
  • 2张巍,鲍春德,顾越英,戴青,杨程德.系统性红斑狼疮继发肺动脉高压35例患者的2年随访结果[J].上海医学,2007,30(8):612-614. 被引量:12
  • 3田庄,刘永太,李梦涛,曾小峰,郭丽琳,朱文玲,方全.结缔组织病合并肺动脉高压患者的右室功能:多普勒组织成像技术研究[J].中国超声医学杂志,2007,23(7):511-513. 被引量:4
  • 4Hochberg MC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J].Arthritis Rheum,1997,40(9):1725.
  • 5Appel GB,Contreras G,Dooley MA,et al.Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis[J].J Am Soc Nephrol,2009,20(5):1103-1112.
  • 6Ong LM,Hooi LS,Lim TO,et al.Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis[J].Nephrology (Carlton),2005,10(5):504-510.
  • 7Chan TM,Tse KC,Tang CS,et al.Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis[J].J Am Soc Nephrol,2005,16(4):1076-1084.
  • 8Hu W,Liu Z,Chen H,et al.Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis[J].Chin Med J (Engl),2002,115(5):705-709.
  • 9Lightstone L.Lupus nephritis:where are we now?[J].Curr Opin Rheumatol,2010,22(3):252-256.
  • 10Kawasaki Y.Mizoribine:a new approach in the treatment of renal disease[J].Clin Dev Immunol,2009,2009:681482.

共引文献21

同被引文献68

引证文献9

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部